Scorpion Venom Peptide Derivative Blocks Enterovirus 71 and Other Viruses at Early Infection Stages

A modified scorpion venom peptide (BmKn2-T5) inhibited enterovirus 71 in a dose-dependent manner during early infection stages in vitro, with less cell toxicity than the parent peptide and additional activity against dengue, Zika, and herpes viruses.

Xia, Zhiqiang et al.·Biomolecules·2024·Preliminary Evidencein vitro
RPEP-09555In vitroPreliminary Evidence2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
in vitro
Evidence
Preliminary Evidence
Sample
N=N/A (in vitro)
Participants
Cell cultures infected with enterovirus 71

What This Study Found

BmKn2-T5 inhibited EV71 dose-dependently in vitro, acting at early stages of the viral cycle. It also suppressed DENV, ZIKV, and HSV-1 replication, suggesting a shared early-stage viral target.

Key Numbers

BmKn2-T5 inhibited EV71 when applied during early stages of infection in cell culture models.

How They Did This

In vitro antiviral testing of BmKn2 and 5 derivatives against EV71 in cell cultures. Time-of-drug-addition experiments identified the affected viral life cycle stage. Cytotoxicity assessed. Cross-tested against dengue, Zika, and HSV-1.

Why This Research Matters

There is no approved antiviral for EV71, which causes significant childhood illness and occasional deaths. A peptide that blocks early viral entry could be developed into a broad-spectrum antiviral, potentially covering multiple unrelated viruses.

The Bigger Picture

Antiviral peptides from animal venoms are an emerging research frontier. Finding a single peptide that works against both enveloped and unenveloped viruses through early-stage inhibition could revolutionize broad-spectrum antiviral development, which currently relies mainly on small-molecule drugs with narrower targets.

What This Study Doesn't Tell Us

In vitro study only — cell culture antiviral activity doesn't guarantee effectiveness in animals or humans. The exact molecular target on the viruses hasn't been identified. Stability, delivery, and safety in vivo are unknown.

Questions This Raises

  • ?What is the specific molecular target that BmKn2-T5 blocks during early viral entry?
  • ?Does BmKn2-T5 show antiviral activity in animal models of EV71 infection?
  • ?Could this peptide be developed as a topical or inhaled antiviral for pediatric use?

Trust & Context

Key Stat:
4 viruses inhibited BmKn2-T5 blocked not only EV71 but also dengue, Zika, and herpes simplex viruses at early infection stages
Evidence Grade:
Preliminary evidence from in vitro cell culture experiments only. No animal or human testing has been conducted.
Study Age:
Published in 2024; cutting-edge antiviral peptide research.
Original Title:
Scorpion Venom Antimicrobial Peptide Derivative BmKn2-T5 Inhibits Enterovirus 71 in the Early Stages of the Viral Life Cycle In Vitro.
Published In:
Biomolecules, 14(5) (2024)
Database ID:
RPEP-09555

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What is enterovirus 71 and why is it dangerous?

EV71 is the main virus behind hand, foot, and mouth disease, which primarily affects young children. While usually mild, it can cause severe neurological complications including brain inflammation and paralysis, and can be fatal. It's especially common in Asia-Pacific countries and has no approved antiviral treatment.

How can one peptide work against such different viruses?

The researchers found that BmKn2-T5 blocks a very early step in infection that appears to be shared across these different viruses. While the exact target isn't yet identified, it likely involves a fundamental process that multiple viruses depend on to enter cells.

Read More on RethinkPeptides

Cite This Study

RPEP-09555·https://rethinkpeptides.com/research/RPEP-09555

APA

Xia, Zhiqiang; Wang, Huijuan; Chen, Weilie; Wang, Aili; Cao, Zhijian. (2024). Scorpion Venom Antimicrobial Peptide Derivative BmKn2-T5 Inhibits Enterovirus 71 in the Early Stages of the Viral Life Cycle In Vitro.. Biomolecules, 14(5). https://doi.org/10.3390/biom14050545

MLA

Xia, Zhiqiang, et al. "Scorpion Venom Antimicrobial Peptide Derivative BmKn2-T5 Inhibits Enterovirus 71 in the Early Stages of the Viral Life Cycle In Vitro.." Biomolecules, 2024. https://doi.org/10.3390/biom14050545

RethinkPeptides

RethinkPeptides Research Database. "Scorpion Venom Antimicrobial Peptide Derivative BmKn2-T5 Inh..." RPEP-09555. Retrieved from https://rethinkpeptides.com/research/xia-2024-scorpion-venom-antimicrobial-peptide

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.